Filing Analysis
Camp4 Therapeutics Corp issued an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the earnings press release.
📋 Key Facts
- Company announced financial results for the quarter ended June 30, 2026.
- The report was filed on August 13, 2026.
- Financial results were released via a press release attached as Exhibit 99.1.
CAMP4 Therapeutics completed the second closing of a private placement on August 3, 2026, following clinical milestones. The transaction involved the issuance of shares and pre-funded warrants to investors and management, raising approximately $50.1 million in gross proceeds.
🚩 Red Flags
- Significant issuance of pre-funded warrants which can lead to future dilution.
- Warrants have an exercise price of only $0.0001, making them nearly equivalent to common stock upon exercise.
📋 Key Facts
- Second Closing occurred on August 3, 2026.
- Issued 10,756,498 Shares at $1.53 per share.
- Issued 21,925,368 Warrant Shares via pre-funded warrants at $1.5299 per warrant.
- Management (CEO, CFO, CMO, and Co-founders) purchased an additional 39,306 shares at $1.65 per share.
- The closing was triggered by clinical milestones: clearance from Australia’s TGA and local Ethics Committee for Phase 1/2 trial of CMP-002.
- Gross proceeds for the second closing were approximately $50.1 million.
Camp4 Therapeutics received regulatory clearance in Australia to begin a Phase 1/2 clinical trial for CMP-002, which triggered a milestone and the ability to initiate a $50.1 million 'Second Closing' of previously arranged financing.
🚩 Red Flags
- Significant potential dilution: Issuance of up to 32.7 million new shares of common stock/warrants.
- Heavy reliance on milestone-based financing triggers (Second Closing Trigger).
📋 Key Facts
- Received clearance from Australia’s Therapeutic Goods Administration and local Human Research Ethics Committee for Phase 1/2 trial of CMP-002 (SYNGAP1-related disorder).
- Achievement of the CTA Milestone under the September 9, 2025 Purchase Agreement.
- The Second Closing Trigger has been satisfied.
- Company is eligible to receive up to approximately $50.1 million in gross proceeds.
- Second Closing involves issuance of up to 32,721,172 shares of common stock or pre-funded warrants.
- Expected closing date for the Second Closing is on or about August 3, 2026.
Camp4 Therapeutics entered into a lease amendment to terminate its Cambridge premises and enter into a new, larger lease in Watertown, MA. The transaction involves significant rent abatement periods and a $2.1 million modification fee.
🚩 Red Flags
- Significant cash outflow of $2.1 million for a lease modification fee.
- Relocation and expansion during what appears to be a critical phase (implied by the need for rent abatement/modifications).
📋 Key Facts
- Entered into First Amendment to the 'Cambridge Lease' with ARE-MA Region No. 59, LLC on Dec 22, 2025.
- The Cambridge Lease (30,760 sq ft) will terminate 30 days after the commencement of the new Watertown lease.
- Base rent for the Cambridge premises is abated from Oct 1, 2025, until the Early Termination Date.
- Entered into a 'Watertown Lease' with ARE-MA Region No. 75, LLC for ~44,000 sq ft at $40.00/sq ft annually.
- The Watertown lease term ends June 30, 2030; includes an option to extend for 5 years at market rent (min $85.00/sq ft).
- Company will pay a $2.1 million Lease Modification Fee to ARE 59 in monthly increments.
- The Watertown lease includes an 'Additional Base Rent Abatement Period' lasting through the 14th month after the Rent Commencement Date.
CAMP4 Therapeutics has entered into a significant research, collaboration, and license agreement with GlaxoSmithKline (GSK) to develop antisense oligonucleotide (ASO) therapeutics for neurodegenerative and kidney diseases. The deal provides immediate liquidity via an upfront payment and offers substantial long-term upside through milestone payments and royalties.
🚩 Red Flags
- The agreement can be terminated by GSK for convenience on a target-by-target basis, reducing the company's long-term control over the assets.
📋 Key Facts
- Entered into a Research, Collaboration and License Agreement with GSK on December 17, 2025.
- GSK to pay a one-time, non-refundable upfront payment of $17.5 million.
- Company is eligible for up to $440 million in development and commercial milestone payments.
- Agreement includes tiered royalties on annual net sales in the low- to mid-single digit range.
- GSK receives an exclusive, worldwide license to research, develop, manufacture, and commercialize compounds targeting specific regulatory RNAs.
CAMP4 Therapeutics Corp. entered into an underwriting agreement with Leerink Partners LLC to offer 5,000,000 shares of common stock at $6.00 per share. The offering is expected to generate approximately $28 million in net proceeds and is scheduled to close around December 19, 2025.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of 5 million new shares.
📋 Key Facts
- Offering size: 5,000,000 shares of common stock
- Price per share: $6.00
- Estimated net proceeds: ~$28.0 million (after discounts and expenses)
- Underwriter: Leerink Partners LLC
- Expected closing date: On or about December 19, 2025
- Shares to be issued via shelf registration statement filed on November 10, 2025
- Includes a 60-day lock-up period for company executives and certain stockholders regarding the sale of shares.
Camp4 Therapeutics Corporation filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the earnings press release issued on November 6, 2025.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Financial results were released via press release in Exhibit 99.1
CAMP4 Therapeutics Corporation issued a press release announcing the initiation of GLP toxicology studies for its candidate CMP-SYNGAP-01. This is a routine regulatory/developmental update regarding their clinical pipeline.
📋 Key Facts
- Company initiated GLP Toxicology Studies for CMP-SYNGAP-01 on October 1, 2025.
- The filing is an Item 7.01 disclosure (Regulation FD Disclosure) rather than a material definitive agreement or financial event.
- The company is classified as an 'emerging growth company'.
Camp4 Therapeutics Corp announced a significant private placement of common stock and pre-funded warrants totaling up to $100.2 million in gross proceeds, split into two tranches. The second tranche is contingent upon achieving a clinical trial application (CTA) milestone and a specific stock price threshold.
🚩 Red Flags
- Significant dilution: Up to ~59 million shares/warrants being issued in total.
- Contingent financing structure: The second $50.1M tranche is tied to a high stock price target ($7.50) and regulatory milestones, creating uncertainty in cash runway predictability.
- Board turnover: Three directors (James Boylan, Ravi Thadhani, M.D., and Paula Ragan, Ph.D.) resigned effective September 9, 2025.
- Registration Rights Agreement includes 'cash penalties' for registration failures.
📋 Key Facts
- Initial closing expected around September 11, 2025, for approximately $50.1 million.
- Second closing of up to $50.1 million contingent on CTA milestone and a $7.50 share price threshold (or waiver).
- Initial offering price: $1.53 per share; Pre-funded warrant price: $1.5299.
- Management included in initial sale: CEO Josh Mandel-Brehm, CFO Kelly Gold, CMO Yuri Maricich, and co-founder Richard Young.
- The company will file registration statements for resale of securities within 60 days of the initial closing.
Camp4 Therapeutics Corporation has filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2025. The filing serves as a formal announcement of the earnings press release issued on August 14, 2025.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information in the press release is furnished, not filed, under Section 18 of the Exchange Act.
Camp4 Therapeutics Corp held its 2025 annual meeting of stockholders on June 11, 2025. The filing reports the election of four Class I directors and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2025.
📋 Key Facts
- Annual Meeting held on June 11, 2025.
- Four nominees elected to Class I director positions: James Boylan, Amir Nashat, ScD, Andrew J. Schwab, and Douglas Williams, PhD.
- Ernst & Young LLP ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
- All proposals passed with significant majority votes.
CAMP4 Therapeutics Corporation issued a press release and updated its corporate slide presentation to share translational data from its SYNGAP1-related disorders program and safety data from its Urea Cycle Disorders program.
📋 Key Facts
- Issued press release regarding SYNGAP1-related disorders program showing increased protein in Non-Human Primates (NHP).
- Reviewed preclinical and Single Ascending Dose (SAD) safety data for the Urea Cycle Disorders program at the 28th ASGCT Annual Meeting.
- Updated corporate slide presentation as of May 2025.
Camp4 Therapeutics Corporation filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025. The filing serves as a formal announcement of the company's recent earnings press release.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes Exhibit 99.1 containing the quarterly earnings press release
- Company is classified as an 'emerging growth company'
Camp4 Therapeutics Corp issued an 8-K to furnish its press release announcing financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 27, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing is a standard disclosure of annual financial results via press release (Exhibit 99.1)
- Company is an emerging growth company
CAMP4 Therapeutics Corporation announced the appointment of two new directors, Dr. Douglas Williams and Dr. Murray Stewart, effective March 17, 2025. The Board size was increased from ten to twelve members to accommodate these appointments.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Dr. Douglas Williams appointed as Class I director and Audit Committee member, effective March 17, 2025.
- Dr. Murray Stewart appointed as Class II director, effective March 17, 2025.
- Board size increased from ten to twelve members.
- Both directors granted options to purchase 17,787 shares of common stock under the 2024 Equity Incentive Plan, vesting monthly over three years.
- Dr. Williams previously served as CEO of Codiak BioSciences and EVP at Sana Biotechnology.
Camp4 Therapeutics issued an 8-K to provide a corporate slide presentation and announce safety data from the Phase 1 clinical trial of CMP-CPS-001. The filing includes a press release detailing results from all four cohorts of the single ascending dose (SAD) portion of the study.
📋 Key Facts
- Released safety data from all four cohorts of the single ascending dose (SAD) portion of the Phase 1 clinical trial for CMP-CPS-001 in healthy volunteers.
- Furnished a corporate slide presentation dated January 2025 as Exhibit 99.1.
- Issued a press release on January 7, 2025, regarding safety data and upcoming milestones (Exhibit 99.2).
Camp4 Therapeutics Corp issued an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of the earnings release.
📋 Key Facts
- Report date: November 21, 2024
- Reporting period: Quarter ended September 30, 2024
- The company is an emerging growth company
- Financial results were released via press release (Exhibit 99.1)
Camp4 Therapeutics Corp has filed an amended certificate of incorporation and bylaws in connection with the consummation of its Initial Public Offering (IPO). These changes restructure the company's capital structure, including the authorization of new share classes.
🚩 Red Flags
- Elimination of stockholder written consent rights (common in IPOs but reduces shareholder power).
- Authorization of 25 million shares of undesignated preferred stock, which can be used to issue potentially dilutive securities without further shareholder votes.
📋 Key Facts
- The filing was triggered by the consummation of the Company's IPO on October 15, 2024.
- Authorized Common Stock increased to 175 million shares.
- Authorized 25 million shares of undesignated preferred stock (issuable via Board approval).
- Eliminated all references to previously existing series of preferred stock.
- Eliminated the ability for stockholders to take action by written consent in lieu of a meeting.
- Amended and restated bylaws include new procedures for stockholder proposals and director nominations.